

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an anti-doping rule violation by Logan Fischer asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an out-of-competition sample collection session on October 22, 2019, in Winnipeg, MB.
2. Mr. Logan Fischer (“the athlete”) was selected for doping control. The sample provided by the athlete returned an adverse finding for Drostanolone, a prohibited substance.
3. Following receipt of the CCES’ assertion of an anti-doping rule violation for the presence of Drostanolone, the athlete failed to dispute the asserted violation within the timelines outlined within the Canadian Anti-Doping Program (CADP) and as a result was deemed to have admitted that he committed the asserted violation, waived his right to a hearing and accepted the proposed consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and carries out the CADP, including providing anti-doping services to national sport organizations and their members.
5. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (Code) and its mandatory International Standards. The CCES has implemented the Code and its mandatory International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The athlete is a member of U SPORTS, and participates in the sport of Football. According to Part C, Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in the activities of, sport organizations adopting it. The CADP was issued for adoption by Canadian sport organizations on October 1, 2014, to be operational on January 1, 2015. U SPORTS adopted the CADP on December 19, 2014. Therefore, as a member of U SPORTS and/or as a participant in U SPORTS sport activities, the athlete is subject to the Rules of the CADP.

Doping Control

7. On October 22, 2019, the CCES conducted an out of competition doping control session in Winnipeg, ON. Testing was conducted on U SPORTS athletes as part of the CCES’ domestic test distribution plan, all pursuant to the CADP.
8. The athlete was notified for doping control and, together with the Doping Control Officer (DCO) from the CCES, completed the sample collection process. The athlete’s sample code number was 4462154.

9. On October 25, 2019, the athlete's sample was received by World Anti-Doping Agency (WADA) accredited laboratory, the INRS-Institut Armand-Frappier (INRS), in Laval, QC.

Results Management

10. The adverse analytical finding was received from the INRS on November 10, 2019. The Certificate of Analysis indicated the presence of Drostanolone.
11. Drostanolone is classified as a prohibited substance on the 2019 WADA Prohibited List.
12. On November 13, 2019, the CCES commenced an initial review into the athlete's adverse finding. On November 19, 2019, in response to the CCES initial review the athlete accepted a voluntary provisional suspension.
13. On November 29, 2019, the CCES formally asserted a violation against the athlete for the presence of a prohibited substance.
14. In accordance with CADP Rule 10.2.1, the standard sanction for an intentional doping violation involving the presence of a prohibited substance (non-specified substance), is a four (4) year period of ineligibility. The CCES proposed the standard four (4) year sanction within its assertion of November 29, 2019.

Confirmation of Violation and Sanction

15. In accordance with CADP Rule 7.10.2, which was specifically referenced within the assertion letter, the CCES informed the athlete on November 29, 2019 that, should the athlete take no further action to dispute the asserted violation within 30 days of the letter (he would be deemed to have waived his right to a hearing and thereby accepts the four (4) year sanction proposed by the CCES.
16. On December 5, 2019, the athlete participated in an Administrative call with the Sport Resolution Centre of Canada (SDRCC) where he was reminded of the specified deadline to request or waive his right to a hearing. Following the athlete's participation on the Administrative call, the CCES adjusted the 30-day deadline for him to request or waive his right to a hearing, to January 6, 2020.
17. On December 19, 2019, the athlete was reminded by email of the provisions of CADP Rule 7.10.2.
18. As no further action was taken by the athlete to dispute the asserted violation by January 6, 2020, the CCES relies on the provisions contained in CADP Rule 7.10.2. Accordingly, effective January 6, 2020 by reason of the deemed Waiver, an anti-doping rule violation has been confirmed against the athlete for the presence of the identified prohibited substances. In accordance with CADP Rule 10.2.1 the sanction for this violation is a four (4) year period of ineligibility, which commenced on November 19, 2019 and concludes on November 18, 2023.
19. In accordance with CADP Rules 7.9.2 and 10.11 the athlete's period of ineligibility will formally conclude on November 18, 2023.

20. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 17th day of January 2020.

A handwritten signature in blue ink, appearing to read 'Jeremy Luke', positioned above a horizontal line.

Jeremy Luke
Senior Director, Sport Integrity
CCES